In your interest.
Online Personal Finance Magazine
No beating about the bush.
Pharma continues to be in the limelight and is poised for more of it, thanks to Ranbaxy’s blockbuster deal with Daiichi of Japan. The market thinks that this takeover has set the stage for smaller companies, particularly those operating in contract research and the manufacturing arena, to be targets of such deals. One such stock is that of Divi’s Laboratories which naturally...